Abstract: The diagnosis of thymic epithelial neoplasms is normally rendered after careful evaluation of their histologic features. In some cases, however, the morphological heterogeneity or overlap with neoplasms of other organ systems can lead to diagnostic uncertainty. On the basis of this, the use of immunohistochemical stains as a diagnostic adjunct has become a popular tool. Although undoubtedly, immunohistochemistry has its role in the diagnosis of difficult cases, to date there are no specific markers that would distinguish thymic epithelial neoplasms from other tumors and interpretation of immunohistochemical results should only ever be made in conjunction with accurate morphologic analysis and careful clinical evaluation. This article will review the current knowledge of the immunohistochemical phenotype of thymic epithelial neoplasms with particular emphasis on its use for diagnostic purposes and the latest advances in this field.
T he thymic gland is a lymphoepithelial organ composed of closely admixed epithelial and lymphoid elements. The gland is divided into lobules each of which in turn contains 2 distinct areas, the cortex and the medulla. Whereas the cortex consists of closely packed T lymphocytes, the so-called thymocytes and only scattered dispersed epithelial cells, the medulla, comprises a large number of epithelial cells and only relatively few lymphocytes. Thymic epithelial neoplasms are tumors derived from the epithelial elements of the thymic gland. They are divided into thymomas, neoplasms of low malignant potential and thymic carcinomas, outright malignant tumors. Both thymomas and thymic carcinomas are tumors that can display a wide morphologic spectrum. While thymomas are neoplasms composed of epithelial cells and thymocytes in varying numbers, thymic carcinomas are entirely epithelial tumors that share identical histologic features with tumors of other organ systems. Sufficient familiarity with the histologic characteristics of thymic epithelial neoplasms often allows diagnosis based on morphology alone, however, immunohistochemistry is sometimes used to confirm the diagnosis or, especially in cases of thymic carcinoma, to exclude metastasis to the mediastinal compartment. Nevertheless it has to be noted that to date no specific marker exists that would unequivocally distinguish tumors of thymic epithelial origin from other epithelial tumors. On the basis of this, immunohistochemistry plays a mere supportive role in this context making complete clinical evaluation the most important aspect in the diagnosis of these tumors. This article will provide an overview of the immunohistochemical properties of thymic epithelial neoplasms with particular focus on their use for diagnostic purposes and will also briefly review markers that have been implicated with a prognostic or predictive value in these tumors.
THYMOMA
Similar to the normal thymic gland, thymomas exhibit an admixture of epithelial and lymphoid elements in varying proportions. On the basis of the shape of the epithelial cells and the proportion of lymphocytes the tumors are classified as spindle cell thymoma [World Health Organization (WHO) types A and AB], thymoma (B1 and B2), and atypical thymoma (B3). 1 In addition, there are special variants of thymoma that often defy classification according to the letters and numbers proposed by the WHO schema. 1 Despite these histologic differences, the immunohistochemical characteristics of all types of thymoma are generally similar but may display some special features depending on the subtype.
True to their epithelial nature, the neoplastic cells of thymoma show positive staining for a range of keratins, for instance pancytokeratin (AE1/AE3) (Fig. 1A) , low-molecular-weight cytokeratin (CAM5.2), highmolecular-weight cytokeratin (34E12), and CK5/6. [2] [3] [4] Other carcinomatous markers such as BerEP4 and MOC31 show a more variable staining pattern decorating up to a third of all cases, respectively. 3 In the last few years a range of novel markers have successfully been applied to thymomas including Pax8, p63, FOXN1, and CD205. Pax8 and p63 have been demonstrated to display diffuse and strong nuclear reactivity in up to 100% of cases 3, [5] [6] [7] (Fig. 2A) , whereas positive staining for FOXN1 and CD205 was found in 89% of spindle cell thymomas (WHO type A) and up to 100% of WHO type AB and B1-3 thymomas. 8 Contrary to thymic carcinoma, expression of c-kit and CD5 is only seen in a minority of thymoma cases. 3, [8] [9] [10] Finally, staining with D2-40, a lymphatic endothelial cell marker, has been identified in as much as 70% of thymomas, preferentially those types rich in epithelial cells (WHO types B2 and B3). [11] [12] The lymphocytic component of thymomas shows an immature T-cell phenotype and these thymocytes can be targeted with lymphocyte common antigen, CD3, CD1a, terminal deoxynucleotidyl transferase (TdT) and CD99 antibodies [13] [14] [15] (Fig. 1B) . However, it should be noted that a small number of CD20-positive B lymphocytes can be found in thymomas, either as scattered single cells or organized in germinal centers 16 (Table 1) .
One of the most commonly encountered problems in mediastinal pathology is the distinction of thymoma, especially those with a rich lymphocytic component (WHO types B1 and B2) from lymphoblastic lymphoma. This is mainly because of the fact that the diagnosis often relies on limited biopsy material obtained at mediastinoscopy. In this scenario, the most useful marker is a pancytokeratin stain: in cases of thymoma this will typically highlight a finely arborized network of interconnecting epithelial cell processes between the lymphocytes manifesting a prominent lace-like pattern [17] [18] [19] (Fig. 1A) . Although lymphomas can entrap non-neoplastic thymic epithelial cells that are visible on keratin immunostains, these cells will be widely separated and not interconnecting allowing distinction from thymoma 20 ( Table 2) .
Most of the existing literature on the immunohistochemical pattern in thymomas is based on the evaluation of the conventional types, that is, the so-called B-type thymomas. Only recently have some investigators specifically evaluated spindle cell and mixed-type thymomas (WHO type A and AB). 15, 21 Generally, these show a similar staining pattern as described above (Fig. 2B) , however, the epithelial cells in these tumors can also show expression of markers not usually associated with these neoplasms: CD20 and CK7 reactivity has been identified in 90% and 83% of spindle cell thymomas, respectively. 15, 21 Another important finding in these studies was the fact that focal staining for calretinin, synaptophysin, bcl-2, and smooth muscle actin (SMA) can be seen in spindle cell thymomas 21 and even thyroid transcription factor 1 (TTF-1)-positive cases have been observed among isolated cases of spindle cell and mixedtype thymomas 21, 22 (Figs. 3A-C) ( Table 3) .
Among the different subtypes of thymoma, several deserve special mention with regard to their immunohistochemical properties. Familiarity not only with the unusual histologic features of these tumors but also their immunohistochemical phenotype is highly important to avoid diagnostic confusion with other neoplasms.
Spindle cell thymoma with papillary or pseudopapillary features is a spindle cell thymoma characterized by a prominent papillary growth pattern. 23 The main differential diagnosis for these cases includes papillary carcinomas of thymic or thyroid origin. The use of immunohistochemical markers in the former case will be futile as both neoplasms express similar immunomarkers and cytologic features of malignancy should be sought to distinguish the 2. In cases of papillary thyroid carcinoma, however, thyroglobulin antibody can help distinguish between these neoplasms being positive in papillary tumors of thyroid origin.
Adenomatoid spindle cell thymoma is a recently described variant of thymoma with a prominent glandular or microvesicular pattern resembling adenomatoid or yolk sac tumors. 24 The spindled epithelial cells of these tumors will express epithelial markers such as CAM5.2 and epithelial membrane antigen (EMA), whereas alpha fetoprotein (AFP) is negative. Calretinin on the other hand, a marker known to label adenomatoid tumors may also show focal staining in the epithelial cells of adenomatoid spindle cell thymoma. 24 Micronodular thymoma with lymphoid hyperplasia is a tumor composed of islands of spindled epithelial cells that are embedded in a prominent lymphoid stroma. The epithelial cells have been shown to stain with cytokeratins (CAM5.2 and AE1/AE3) and focally with bcl-2. 25, 26 The more important aspect in this type of thymoma is the lymphoid stroma which is composed of a mixture of mature B (CD20 + ) and T (CD3 + , CD5 + ) lymphocytes; immature T cells (CD1a + , CD99 + ) like commonly seen in thymomas are present only in scattered form. 15, 25, 26 These tumors have the potential to be mistaken for metastatic carcinoma or sarcoma to a lymph node; careful search for cytologic atypia and increased mitotic activity in the latter should help distinguish these tumors. 25 Analogous to conventional thymoma, the so-called atypical thymoma with pseudosarcomatous stroma contains an epithelial component that shows reactivity for cytokeratin (CK), CAM5.2, EMA, AE1/AE3, p63, and e-cadherin. 27 In addition, these tumors contain a second stromal spindle cell component that shows a more variable immunophenotype and in addition to vimentin may show focal staining with SMA or even epithelial markers. [27] [28] [29] [30] The scarce lymphoid component is identical to that seen in conventional thymomas and consists primarily of CD3 + , CD99 + , TdT + T lymphocytes. 27, 29 As the name implies plasma cell-rich thymoma contains abundant stromal plasma cells of polyclonal nature. 31 Although plasma cells may be present in the normal thymus, their occurrence in thymomas is extremely rare and is often associated with autoimmune disorders in this context. [31] [32] [33] Cytokeratin will positively stain the epithelial cells of this thymoma, whereas kappa and lambda stains can be used to label the plasma cell component and assess clonality. 31 Appl
Ancient (sclerosing) thymoma shows extensive stromal sclerosis that can obscure the epithelial elements of these tumors making the use of a cytokeratin stain necessary to identify the epithelial nature of the tumor. 34, 35 Fortunately, the differential diagnosis for these tumors primarily includes keratin-negative lesions such as sclerosing mediastinitis, solitary fibrous tumor, or Hodgkin lymphoma allowing for distinction between these entities. 34, 35 Two distinct cell populations characterize rhabdomyomatous thymomas. In these tumors, epithelial and myoid elements are closely intermixed. 36 The epithelial component can be targeted with stains such as AE1/AE3, CK, and BerEP4, whereas the myoid cells react with myoglobin, desmin, and vimentin. 36, 37 Awareness of this unusual tumor is important not to mistake this lesion for a tumor of pure skeletal muscle lineage or a carcinosarcoma.
Thymoma with signet ring cell-like features is a type of thymoma that strongly mimics signet ring cell adenocarcinoma or even yolk sac tumors. 38 The tumor cells show reactivity for CK, AE1/AE3, CAM5.2, and CK5/6 and are negative for markers such as AFP, TTF-1, calretinin, CD31, S100, vimentin, and carcinoembryonic antigen (CEA). This staining pattern together with an absence of cytologic atypia helps classify these tumors as thymoma. 38, 39 Finally, thymomas characterized by abundant stromal changes such as hyalinized or myxoid collagen admixed with a young fibroblastic proliferation exist (desmoplastic spindle cell thymoma). 40 The spindled epithelial cells of these tumors show immunoreactivity for cytokeratin, CK5/6, vimentin, Pax8, and bcl-2 and lack expression of markers such as desmin, EMA, SMA, S100, and CD34 setting them apart from other tumors such as solitary fibrous tumor or synovial sarcoma.
THYMIC CARCINOMA
Thymic carcinomas are a group of malignant epithelial tumors of the thymus that display a wide morphologic spectrum. Contrary to thymomas, these tumors show unequivocal cytologic features of malignancy and lack the typical lymphocytic component associated with the majority of thymomas. There are no specific histologic features that would distinguish thymic carcinomas from tumors of other organ systems and metastatic disease to the thymic gland needs to be ruled out clinically before a diagnosis of primary thymic carcinoma can be rendered. A wide range of thymic carcinoma subtypes exist of which squamous cell, high-grade undifferentiated and lymphoepithelioma-like carcinoma types are the most common. 41 Although tumor subtype does not appear to have significant prognostic value, correct diagnosis in nonetheless required for appropriate classification. 41 In general, the tumor cells in thymic carcinoma are characterized by diffuse immunoreactivity for a range of cytokeratins including pancytokeratin, CK5/6 and CK7 as well as p63 3, [42] [43] [44] [45] [46] [47] (Figs. 4A, B) . In a similar fashion to thymoma, 2 novel markers, Pax8 and FOXN1 have recently been shown to be expressed by the majority of thymic carcinomas (Figs. 2C, 4C ). This immunoreactivity is a valuable tool especially in the differential diagnosis from non-small cell lung cancer as these markers are usually negative in primary lung carcinoma cases 
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Appl Immunohistochem Mol Morphol Volume 22, Number 7, August 2014 (Table 4) . 5, 8, 41 Contrary to thymoma, thymic carcinomas show more variation of staining with CD205 with only approximately 10% to 60% of cases showing expression of this marker. 8, 41 In contrast, thymomas and thymic carcinomas display a marked difference in their staining for c-kit; whereas thymomas are largely negative for this marker, thymic carcinomas have been shown to be positive in up to 86% of cases 9, 41, 48, 49 (Fig. 4D ). In the past, CD5 had received acclaim for its supposed high expression in thymic carcinoma cells and negative expression in many other neoplasms. 3, 48, [50] [51] [52] In the last few years, however, it could be demonstrated that this marker is also expressed by a range of other carcinomas as well as atypical thymomas (WHO type B3), limiting the use of this antibody for the definitive diagnosis of primary thymic carcinoma. 47, 48, 53 In addition, a study evaluating a large series of thymic carcinoma showed that <40% of cases of thymic carcinoma were positive for this marker 41 ( Fig. 4E) . It should also be acknowledged that immunohistochemical evidence of neuroendocrine differentiation is not an uncommon finding in thymic carcinomas 54 ; patchy expression of synaptophysin, neuron-specific enolase, and chromogranin has been identified in thymic carcinomas that lack the typical appearance of a neuroendocrine tumor. On that account it has to be stressed that these carcinomas should not be regarded as neuroendocrine carcinomas but rather as thymic carcinomas with neuroendocrine differentiation, the prognosis of which does not appear to differ from conventional thymic carcinomas. 54 Another important issue with thymic carcinomas is the fact that these tumors can be positive for calretinin in a significant number of cases (Fig. 4F) ; this should be kept in mind when the differential diagnosis includes mesothelial-derived lesions. 3, 41 Three additional markers that are deemed useful for distinguishing thymoma from thymic carcinoma are glucose transporter 1 (GLUT-1), L-type amino acid transporter 1 (LAT1), and mucin 1 (MUC1); these markers are significantly higher expressed in thymic carcinomas than in thymomas. 49, 55, 56 TTF-1, napsin, and CD30 have been consistently negative in thymic carcinomas rendering these markers very useful for differential diagnostic considerations 3, 46, 47, 50, 57, 58 (Tables 1 and 4) . Apart from the more common types of thymic carcinoma, there are several tumor subtypes that show distinct morphologic features and can vary in their immunohistochemical properties due to their cell composition. As with thymomas, awareness of these entities is important in order not to mistake these tumors for neoplasms of a different grade or a metastatic process.
Mucinous adenocarcinomas of the thymus are very rare tumors that show morphologic overlap with metastatic mucinous carcinomas, especially those of colon or lung origin. Expression of CK and CK7 is usually identified in these tumors; more variable reactivity is seen with CK20, CD5, and CDX2 (Fig. 5) . Negative markers include TTF-1, surfactant protein-a, napsin, and Pax8. [59] [60] [61] [62] 41 Clear cell carcinomas of the thymus generally show a positive reaction for CK (both low-molecular-weight and high-molecular-weight cytokeratins). Variable staining has been described for CD5, CEA, and EMA, whereas Pax8, FOXN1, p63, CK5/6, and TTF-1 are ususally negative. 41, 63, 64 Micronodular thymic carcinoma with lymphoid hyperplasia is the counterpart to micronodular thymoma, the discriminating factor being overt cytologic atypia in the epithelial cells of the former. 65 Common to both tumors is the prominent lymphoid stroma composed of a mixture of mature B (CD20 + ) and T (CD3 + /TdT À ) cells. Kappa and lambda stains failed to demonstrate a monoclonal proliferation. 65 A very rare type of thymic tumor is the so-called hepatoid thymic carcinoma. This tumor strongly resembles hepatocellular carcinoma based on its large polygonal tumor cells. 58 Expression of CK7, CK19, a-1-antitrypsin, a-1-antichymotrypsin, and Hepar1 has been reported in this tumor in the absence of staining for AFP, placental alkaline phosphatase, or CD5 among others. Intratumoral CD1a + or TdT + lymphocytes were not identified. 58 Care should be taken not to mistake papillary thymic carcinoma for metastatic papillary carcinoma of thyroid or lung origin. The tumor cells in the former show reactivity for CEA, BerEP4, CD15, and variable staining for calretinin and CD5. 66, 67 Contrary to their thyroid or lung counterparts, thyroglobulin and surfactant protein-a are reported to be negative in these tumors. 66, 67 Thymic carcinomas showing prominent rhabdoid cytoplasmic inclusions have been named thymic carcinoma with rhabdoid features. These tumors are extremely rare and only few cases have been described in the literature. Limited immunohistochemical studies in these tumors have revealed a CK + , FOXN1
+ immunophenotype with focal staining also for CK7 and vimentin. 41, 57 
CK indicates cytokeratin; EMA, epithelial membrane antigen; TEN, thymic epithelial neoplasms.
As the name implies spindle cell thymic carcinomas are characterized by their fusiform cell morphology. These tumors are easily mistaken for mediastinal sarcomas. Immunohistocemically, however, the spindle cells are positive for pancytokeratin and CAM5.2, whereas EMA and vimentin may show variable staining results.
Other markers such as actin, desmin, S100 protein, HMB45, CD34, CD5, and CD99 are usually negative. 68, 69 Another unique group of thymic carcinomas are salivary gland-type carcinomas. In the thymus, this group of tumors includes mucoepidermoid and adenoid cystic carcinoma. Although immunohistochemical analysis does 
Appl Immunohistochem Mol Morphol Volume 22, Number 7, August 2014 not usually play a major role in the diagnosis of salivary gland-type tumors, thymic mucoepidermoid carcinomas have been reported to express CK, CK7, CK20 with variable staining also for CD5, whereas TTF-1, synaptophysin, chromogranin A, S100, CD99, and MUC2 were negative. 8, 70 Thymic adenoid cystic carcinomas are even rarer than thymic mucoepidermoid carcinomas, however, limited reports have demonstrated positive staining of the tumor cells for CK5/6, p63, 34bE12, along with focal synaptophysin reactivity. In contrast, CD5, ckit, chromogranin A, and CD56 appear to be uniformly negative in these tumors. 71, 72 
PROGNOSTIC AND PREDICTIVE MARKERS FOR THYMIC EPITHELIAL NEOPLASMS
Immunohistochemical markers have not only been used for diagnostic purposes but are also increasingly used to predict prognosis. The last few years have shown an increasing number of publications investigating the use of immunohistochemistry to predict clinical outcome in thymic epithelial neoplasms. Aggressive disease, increased metastatic potential, and reduced survival have been described in tumors expressing p53, 73 high-molecularweight cytokeratin 34bE12, 74 LAT1, 55 GLUT-1, 49 IGF1R and p-AKT, 75 c-kit, 10 podoplanin, 12 and MUC1. 56 Contrary to that, expression of estrogen receptors is inversely correlated to tumor size, clinical stage, WHO type, and Ki67 labeling resulting in better prognosis. 76 Like for many other solid tumors, epidermal growth factor receptor and HER2 protein overexpression has been demonstrated in both thymomas and thymic carcinomas. [77] [78] [79] [80] [81] [82] [83] However, contradicting results have emerged with regard to prognostic utility. [84] [85] [86] [87] [88] 
SUMMARY
In today's practice of surgical pathology immunohistochemistry plays a vital role by either establishing or confirming a diagnosis. This also applies to the pathologic assessment of thymic epithelial neoplasms. Although unfortunately no specific marker exists for these tumors, a panel of several markers can be used with good success to differentiate these tumors from other neoplasms. Promising new markers to use in such a panel include Pax8 and FoxN1 besides the more traditional cytokeratin and CD5 stains. Use of these markers in combination with relevant negative stains should aid in making the correct diagnosis in most cases, however, clinical and radiologic findings should never be underestimated and still play a major role in the assessment of mediastinal masses. 
